Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents

Jumpei Teramachi, Hirokazu Miki, Shingen Nakamura, Masahiro Hiasa, Takeshi Harada, Masahiro Abe

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Introduction: Multiple myeloma (MM) is a malignancy of plasma cells with characteristic bone disease. Despite recent great strides achieved in MM treatment owing to the implementation of new anti-MM agents, MM is still incurable and bone destruction remains a serious unmet issue in patients with MM. Approach: In this review, we will summarize and discuss the mechanisms of the formation of bone disease in MM and the available preclinical and clinical evidence on the treatment for MM bone disease. Conclusions: MM cells produce a variety of cytokines to stimulate receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis and suppress osteoblastic differentiation from bone marrow stromal cells, leading to extensive bone destruction with rapid loss of bone. MM cells alter the microenvironment through bone destruction where they colonize, which in turn favors tumor growth and survival, thereby forming a vicious cycle between tumor progression and bone destruction. Denosumab or zoledronic acid is currently recommended to be administered at the start of treatment in newly diagnosed patients with MM with bone disease. Proteasome inhibitors and the anti-CD38 monoclonal antibody daratumumab have been demonstrated to exert bone-modifying activity in responders. Besides their anti-tumor activity, the effects of new anti-MM agents on bone metabolism should be more precisely analyzed in patients with MM. Because prognosis in patients with MM has been significantly improved owing to the implementation of new agents, the therapeutic impact of bone-modifying agents should be re-estimated in the era of these new agents.

Original languageEnglish
Pages (from-to)388-403
Number of pages16
JournalJournal of Bone and Mineral Metabolism
Issue number3
Publication statusPublished - May 2023


  • Bone-modifying agents
  • Daratumumab
  • Myeloma bone disease
  • Proteasome inhibitors
  • Receptor activator of nuclear factor-κB ligand

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology


Dive into the research topics of 'Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents'. Together they form a unique fingerprint.

Cite this